SWOG clinical trial number
SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415)
Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer, Intergroup.
Abbreviated Title
High Risk Resectable Colon
Treatment
5-Fluorouracil
Leucovorin Calcium
Levamisole
2015
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population [Collaborators: K Guthrie, C Blanke] (https://www.ncbi.nlm.nih.gov/pubmed/25697217)
LA Renfro;A Grothey;D Kerr;DG Haller;T Andre;E Van Cutsem;L Saltz;R Labianca;CL Loprinzi;SR Alberts;H Schmoll;C Twelves;G Yothers;DJ Sargent Annals of Oncology May;26(5):950-958; 2015
PMid: PMID25697217 | PMC number: PMC4405281
2011
Outcomes among black patients with stage II/III colon cancer receiving adjuvant chemotherapy: an accent group analysis [PMID21997132; PMC3196480]
G Yothers;D Sargent;N Wolmark;R Goldberg;M O'Connell;J Benedetti;L Saltz;J Dignam;A Blackstock Journal of the National Cancer Institute 103(20):1498-1506; JAMA
2010
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set [PMC2815708; PMID20008641]
A de Gramont;J Hubbard;Q Shi;M O'Connell;M Buyse;J Benedetti;B Bott;C O'Callaghan;G Yothers;RM Goldberg;CD Blanke;A Benson;Q Deng;S Alberts;T Andre;N Wolmark;A Grothey;D Sargent Journal of Clinical Oncology 28(3):460-465
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) - findings from the ACCENT dataset
T Andre;Q Shi;G Yothers;BM Bott;G Haller;E Van Cutsem;J Cassidy;J Benedetti;M O'Connell;DJ Sargent Journal of Clinical Oncology 28:15s (suppl; abstr 3616); ASCO Annual Meeting; poster
Obesity is an independent prognostic variable in colon cancer survivors [PMID20215553; PMC2948494]
F Sinicrope;NR Foster;DJ Sargent;MJ O'Connell;C Rankin Clinical Cancer Research 16(6):1884-1893
2008
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set [PMID:18467725]
MJ O'Connell;ME Campbell;R Goldberg;A Grothey;J Seitz;JK Benedetti;T Andre;DG Haller;DJ Sargent Journal of Clinical Oncology 26(14):2336-2341
2007
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the Accent group [PMID17876008]
DJ Sargent;S Patiyil;G Yothers;DG Haller;R Gray;J Benedetti;M Buyse;R Labianca;JF Seitz;C O'Callaghan;G Francini;A Grothey;M O'Connell;PJ Catalano;D Kerr;E Green;HS Wieand;RM Goldberg;de Gramont Journal of Clinical Oncology 25(29):4569-4574
2005
Phase III Southwest Oncology Group 9415/ Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer
EA Poplin;JK Benedetti;NC Estes;DG Haller;RJ Mayer;RM Goldberg;GR Weiss;SE Rivkin;JS Macdonald Journal of Clinical Oncology 23(9):1819-1825
2000
Phase III randomized trial of bolus 5-FU/leucovorin/levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153)
E Poplin;J Benedetti;N Estes;D Haller;R Mayer;R Goldberg;J Macdonald Proc of the American Society of Clinical Oncology 19:240a(#931)
